Geron Q4 2022 Earnings Report $2.62 +0.08 (+2.95%) As of 02/20/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Geron EPS ResultsActual EPS-$0.10Consensus EPS -$0.11Beat/MissBeat by +$0.01One Year Ago EPS-$0.10Geron Revenue ResultsActual Revenue$0.10 millionExpected Revenue$0.12 millionBeat/MissMissed by -$20.00 thousandYoY Revenue GrowthN/AGeron Announcement DetailsQuarterQ4 2022Date3/16/2023TimeAfter Market ClosesGERN Upcoming EarningsGeron will be holding an earnings conference call on Wednesday, February 26 at 8:00 AM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesConference CallConference Call TranscriptGERN Earnings History Geron Earnings HeadlinesB. Riley Comments on Geron's FY2027 Earnings (NASDAQ:GERN)February 21 at 3:31 AM | americanbankingnews.comGeron Corp (GERN) Announces Equity Awards to New EmployeesFebruary 20 at 8:30 PM | gurufocus.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. February 21, 2025 | Crypto 101 Media (Ad)B. Riley Has Lowered Expectations for Geron (NASDAQ:GERN) Stock PriceFebruary 20 at 2:45 AM | americanbankingnews.comB.Riley senkt Kursziel für Geron-Aktie auf 3,50 US-Dollar, behält Kaufempfehlung beiFebruary 19 at 11:48 AM | de.investing.comIs Geron Corp. (GERN) the Best Nasdaq Stock Under $5 to Buy?February 12, 2025 | insidermonkey.comSee More Geron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Geron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Geron and other key companies, straight to your email. Email Address About GeronGeron (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.View Geron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
